Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
March 23, 2021 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in patients with COVID-19 severe...
March 16, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
March 15, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings...
March 11, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
March 10, 2021 08:00 ET | Source: aTyr Pharma, Inc.

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
February 25, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at March Investor Conferences

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
February 11, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 ...
February 09, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at BIO CEO & Investor Digital Conference

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
January 25, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression

Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 ...